Baxter Approved for New Advate Strength
ADVATE (antihemophilic factor [recombinant] plasma/albumin-free method) 4000IU for IV use by Baxter
Baxter announced that the FDA has approved a new 4000 IU dosage strength of Advate (Antihemophilic Factor VIII [recombinant], plasma/albumin-free injection). The new 4000 IU dosage strength provides a single vial dosing opportunity, including some patients on a dosing schedule of every three days for prophylactic treatment with Advate.
Advate, a clotting factor, is indicated in patients with Hemophilia A to control and prevent hemorrhagic episodes, for perioperative management, and routine prophylaxis to prevent or reduce the frequency of hemorrhagic episodes.
Advate is already available 250 IU, 500 IU, 1000 IU, 1500 IU, 2000 IU, 3000 IU dosage strengths. The 4000 IU strength will be available to patients in August 2012.
For more information call (800) 423-2090 or visit www.advate.com.